October 03, 2011Palau Pharma sells to Draconis Pharma its Drug Discovery Unit and will focus on the development of its late-stage clinical pipeline... read more +

December 17, 2010Palau Pharma Initiates Phase II Clinical Trial of its histamine H4 receptor antagonist UR-63325... read more +

September 01, 2010Palau Pharma, member of the Board of Directors of the European Biopharmaceutical Enterprises... read more +

June 08, 2010Palau Pharma reports positive First-in-Man clinical trial results for its histamine H4 receptor antagonist UR-63325... read more +

March 08, 2010Palau Pharma unveils its new website today... read more +

February 16, 2010NEOGENIUS, the alliance between Almirall, Esteve, Palau Pharma and Proteomika, is to investigate new medicines for the treatment of osteoarthritis-induced pain... read more +

July 20, 2009Palau Pharma starts a Phase I clinical trial with a novel histamine H4 receptor antagonist... read more +

April 20, 2009Palau Pharma Initiates a Phase II Clinical Trial of Dersalazine Sodium in Mild to Moderate Ulcerative Colitis... read more +

May 07, 2008Palau Pharma's Partner, Iberhospitex, gains CE Approval for the Coronary Drug-Eluting Stent ACTIVE®... read more +

January 23, 2007Affectis Pharmaceuticals AG In-licenses Clinical Stage Compound for the Treatment of Psychiatric Disorders... read more +

November 01, 2006GRUPO URIACH launches Palau Pharma with the collaboration of several financial investors... read more +